Business Context and Reporting Period
This Form 8-K filing by Pharmacyte Biotech, Inc. (PMCB) was submitted on November 9, 2023, reporting events occurring on November 5, 2023. The company is incorporated in Nevada and trades on The Nasdaq Stock Market LLC. The filing addresses a change in the registrant's certifying accountant.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance regarding the independent auditor.
Material Changes
- Resignation of Former Auditor: Armanino LLP resigned as the independent registered public accounting firm on August 1, 2023. The resignation was initiated by Armanino due to a strategic decision to exit the practice of providing audit services to all public company engagements, not due to any actions by the Company.
- Appointment of New Auditor: On November 5, 2023, the Company engaged Marcum LLP as its new independent registered public accounting firm.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. Regarding the auditor transition, the Company confirmed that during the two fiscal years ended December 31, 2021 and 2022, and the interim period through November 5, 2023, there were no consultations with Marcum LLP regarding accounting principles or disagreements with the former auditor. No unusual items or contingencies were disclosed.
Investor Verification Checklist
- Verify the effective date of the new audit engagement with Marcum LLP.
- Review the Company's most recent 10-K or 10-Q filings to assess financial health, as this 8-K contains no financial data.
- Monitor future filings for the first audit opinion issued by Marcum LLP to ensure no undisclosed issues arise.
- Confirm the status of the interim leadership team, noting the signature by Interim CEO Joshua N. Silverman.